Company Overview and News

8
Tan-led Infracorp eyes O&M partner for Skytrain

2018-06-17 bworldonline
INFRACORP Development, Inc. is currently looking for an operations and maintenance (O&M) partner for its P3.5-billion Skytrain project, saying it is speaking with several firms from Austria, France, Japan and China.
ALGGY ALGGF AYAAY AGI ALI AYAAF

3
Megaworld to launch P80-B worth of projects this year

2018-06-15 bworldonline
Megaworld Corp. is scaling up its residential project launches to P80 billion this year, banking on the continued strong demand for properties from both local and foreign buyers.
ALGGY GERI ALGGF AGI

5
GERI eyes P8 billion in sales from Ortigas condo

2018-06-10 bworldonline
GLOBAL-ESTATE Resorts, Inc. (GERI) is aiming to generate P8 billion in sales from its fifth residential condominium in Ortigas Center, banking on its proximity to educational institutions and key business districts.
ALGGY GERI ATB ALGGF AGI

9
Andrew Tan steps down as AGI chief executive

2018-06-04 bworldonline
TYCOON Andrew L. Tan has stepped down as chief executive officer of holding company Alliance Global Group, Inc. (AGI), appointing eldest son Kevin Andrew L. Tan to take his place.
PSKXF RWM ALGGY ALGGF GERI PHSXY PSE ELI AGI

14
AGI gets go signal for Skytrain

2018-05-28 bworldonline
THE infrastructure arm of tycoon Andrew L. Tan’s Alliance Global Group, Inc. (AGI) bagged the original proponent status (OPS) for its proposed P3-billion monorail project connecting Fort Bonifacio to the Guadalupe station of the Metro Rail Transit (MRT) Line 3.
FILIY JGSMY ALGGY RWM JGS MPI MPCFF MPCIY ALGGF FDC AGI JGSHF

3
AGI unit bags original proponent status for Skytrain

2018-05-28 bworldonline
The infrastructure arm of tycoon Andrew L. Tan’s Alliance Global Group, Inc. (AGI) bagged the original proponent status (OPS) for its proposed P3-billion monorail project connecting Fort Bonifacio to the Guadalupe station of the Metro Rail Transit (MRT) Line 3.
ALGGY ALGGF AGI

3
DoTr endorses Andrew Tan’s P3B BGC-Makati monorail project

2018-05-28 business.inquirer.net
The group of tycoon Andrew Tan has bagged the original proponent status for the unsolicited proposal to build a P3-billion two-kilometer “Skytrain” monorail that will link Fort Bonifacio and MRT Guadalupe Makati.
ALGGY ALGGF AGI

23
DoTr may green-light consortium’s NAIA rehabilitation plan in two weeks

2018-05-25 bworldonline
THE Department of Transportation (DoTr) may grant within the next two weeks the original proponent status (OPS) to the consortium seeking to rehabilitate the Ninoy Aquino International Airport (NAIA).
JGSMY JGS MPCIY PXMFF GMQRY GMRINFRA 532754 FILIY PX ALGGY MWP MPI MPCFF ALGGF FDC AGI MWIDE PXMFY JGSHF

3
Getting to know The Dalmore—and tasting it

2018-05-22 lifestyle.inquirer.net
The four-hour train ride from King’s Cross in London began with an idyllic, rather flat countryside. Beyond the River Tweed, the terrain slowly transformed into a vast, rocky coastline, with the train weaving through roofed hamlets, rolling greens and acres of unblemished Scottish countryside.
ALGGY ALGGF AGI

16
Consortium cuts period, cost for proposed NAIA rehab

2018-05-22 bworldonline
THE CONSORTIUM formed by some of the country’s conglomerates has submitted a revised proposal to rehabilitate the Ninoy Aquino International Airport (NAIA), cutting the project duration from 35 years to 15 years.
JGSMY JGS MPCIY GMQRY GMRINFRA 532754 FILIY ALGGY MWP MPI MPCFF ALGGF FDC AGI MWIDE JGSHF

3
Andrew Tan receives Spanish civil merit award

2018-05-18 lifestyle.inquirer.net
Dr. Andrew L Tan (right) receives the merit medal from Spanish Ambassador Luis Calvo, as Finance Secretary Carlos Dominguez III looks on.
ALGGY ALGGF AGI

51
Conglomerates deliver mixed Q1 results, but outlook remains positive

2018-05-15 bworldonline
CONGLOMERATES are expected to register better financial results this year, as the country’s top firms proceed with expansion programs amid a new tax regime and challenges in their respective businesses.
JGSMY GTCAP GTCXY SVTMF SMCP1 JGS SM AEV SMGBF SMIVY SMC ALGGY MPCFF PHSXY PSE AGI JGSHF DMC PSKXF MPCIY LPZ DMCIF SMGBY DMCP SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E ALGGF DMCHY LTG

8
AGI nets P3.5B

2018-05-15 business.inquirer.net
Tycoon Andrew Tan-led conglomerate Alliance Global Group Inc. (AGI) posted P3.5 billion in first quarter net profit attributable to equity holders of parent firm, down by 2 percent year-on-year, on slower earnings from integrated gaming operations alongside higher interest charges and foreign exchange losses.
PSKXF ALGGY ALGGF PHSXY PSE AGI

37
Gateway airport decision up to future governments — NEDA

2018-05-13 bworldonline
A FUTURE government will end up making the decision to designate a main international gateway airport for Metro Manila, the National Economic and Development Authority (NEDA) said, due to the long timelines for the airports under development around the nation’s capital.
JGSMY SMCP1 JGS MPCIY SMGBY SMGBF FILIY SMC2B SMC2A SMC SMC2D ALGGY SMC2C MWP MPI MPCFF SMC2F SMC2E ALGGF FDC AGI MWIDE JGSHF

9
Stocks end week in rally mode

2018-05-11 bworldonline
Stocks continued to rise on the trading week’s end following the central bank’s decision to increase interest rates on Friday, May 11.
LOTO PSKXF RBLAY AEV RLC ALGGY ABTZY ALGGF PHSXY PSE AGI BBRRF BLOOM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...